These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35371995)

  • 1. Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer.
    Li Q; Cheng X; Zhou C; Tang Y; Li F; Zhang B; Huang T; Wang J; Tu S
    Front Oncol; 2022; 12():841977. PubMed ID: 35371995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of Fruquintinib and Anti-PD-1 for the Treatment of Colorectal Cancer.
    Wang Y; Wei B; Gao J; Cai X; Xu L; Zhong H; Wang B; Sun Y; Guo W; Xu Q; Gu Y
    J Immunol; 2020 Nov; 205(10):2905-2915. PubMed ID: 33028620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study.
    Ma S; Chen R; Duan L; Li C; Yang T; Wang J; Zhao D
    J Gastrointest Oncol; 2023 Apr; 14(2):1052-1063. PubMed ID: 37201046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety, and predictors of fruquintinib plus anti-programmed death receptor-1 (PD-1) antibody in refractory microsatellite stable metastatic colorectal cancer in a real-world setting: a retrospective cohort study.
    Yang X; Yin X; Qu X; Guo G; Zeng Y; Liu W; Jagielski M; Liu Z; Zhou H
    J Gastrointest Oncol; 2023 Dec; 14(6):2425-2435. PubMed ID: 38196544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer: A retrospective study.
    Zhang W; Zhang Z; Lou S; Li D; Ma Z; Xue L
    Front Oncol; 2022; 12():929342. PubMed ID: 36119532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant response from fruquintinib plus anti-PD-1 immunotherapy for microsatellite stable metastatic colorectal cancer with liver and lung metastasis in the third line: case report.
    He L; Cheng X; Zhou C; Li Q; Zhang B; Cheng X; Donadon M; Mannavola F; Tu S
    J Gastrointest Oncol; 2023 Dec; 14(6):2617-2626. PubMed ID: 38196522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study.
    Nie C; Lv H; Chen B; Xu W; Wang J; Liu Y; Wang S; Zhao J; He Y; Chen X
    Front Oncol; 2022; 12():917353. PubMed ID: 36226061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.
    Guo Y; Zhang W; Ying J; Zhang Y; Pan Y; Qiu W; Fan Q; Xu Q; Ma Y; Wang G; Guo J; Su W; Fan S; Tan P; Wang Y; Luo Y; Zhou H; Li J
    Eur J Cancer; 2023 Mar; 181():26-37. PubMed ID: 36628898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report.
    Lin S; Chen W; Chen Z; Liang J; Zhong L; Jiang M
    Ann Transl Med; 2022 Mar; 10(6):380. PubMed ID: 35433988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China.
    Gou M; Qian N; Zhang Y; Yan H; Si H; Wang Z; Dai G
    Front Oncol; 2022; 12():851756. PubMed ID: 35875064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fruquintinib in combination with sintilimab or TAS-102 as third-line or above treatment in patients with metastatic colorectal cancer: a real-world study.
    Li L; Wang T; Wu Z; Li Y; Ma H; Wang L; Lei S; Chen W
    Transl Cancer Res; 2023 Nov; 12(11):3034-3044. PubMed ID: 38130300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth.
    Doleschel D; Hoff S; Koletnik S; Rix A; Zopf D; Kiessling F; Lederle W
    J Exp Clin Cancer Res; 2021 Sep; 40(1):288. PubMed ID: 34517894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215).
    Zhao W; Lei J; Ke S; Chen Y; Xiao J; Tang Z; Wang L; Ren Y; Alnaggar M; Qiu H; Shi W; Yin L; Chen Y
    EClinicalMedicine; 2023 Dec; 66():102315. PubMed ID: 38024475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable responses to tislelizumab plus fruquintinib and radiotherapy in refractory microsatellite stable metastatic colorectal cancer: a case report.
    Zhao W; Huang Z
    Am J Transl Res; 2023; 15(4):2918-2925. PubMed ID: 37193166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report.
    Wan Y; Luo D
    J Gastrointest Oncol; 2023 Feb; 14(1):450-457. PubMed ID: 36915460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer.
    Sun L; Huang S; Li D; Mao Y; Wang Y; Wu J
    Front Oncol; 2021; 11():754881. PubMed ID: 34692541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.